Validated HPTLC Method for Simultaneous Estimation of Sitagl | 54980

International Journal of Applied Biology and Pharmaceutical Technology


Validated HPTLC Method for Simultaneous Estimation of Sitagliptin and Metformin Hydrochloride in Bulk Drug and Formulation

Emir Ehsaan

A straightforward, exact, precise and fast superior meager layer chromatographic strategy has been created and approved for the synchronous estimation of two enemy of diabetic medications, sitagliptin and metformin hydrochloride in mass and tablet measurement structure. Study was performed on TLC plates precoated with silica gel 60F254 utilizing methanol: smelling salts: icy acidic corrosive (9.4:0.4:0.2 v/v/v)as the versatile stage. A TLC scanner set at 214 nm was utilized for direct assessment of the chromatograms in the absorbance mode. Strategy was approved by ICH rules. The relationship coefficients of adjustment bends were seen as 0.999 and 0.998 in the fixation scope of 100–1100 and 1000–11000 ng band-1for sitagliptin and metformin, separately. The technique had an exactness of 99.70% for sitagliptin and 100.02% for metformin hydrochloride. Intra and entomb day exactness estimated as coefficient of variety were under 2% for both analytes. The restriction of location and quantitation were 7.08 ng band-1 and 21.82 ng band-1, individually for sitagliptin and 19.31 ng band-1 and 58.51 ng band-1, separately for metformin hydrochloride. The strategy could decide these medications at the same time from measurement structure with no impedance of the tablets excipients Presentation: Sitagliptin(STG),(2R)- 1-(2,4,5-trifluorophenyl)- 4-oxo-4-[3-(trifluoromethyl)- 5,6dihydro [1,2,4] triazolo [4,3-a] pyrazin - 7 (8H)- yl] butan-2- amine, is an orally dynamic, intense and specific inhibitor of dipeptidyl peptidase-IV (DPP-IV), which has been ma0rketed in USA, Europe and different nations for the treatment of type 2 diabetes. DPP-IV inhibitors upgrade levels of dynamic glucagon-like peptide 1 (GLP-1) and different incretins, and encourage glucose-subordinate insulin emission. Metformin (MET) (N,N-dimethylbiguanide, initially showcased as Glucophage TM by Bristol-Myers Squibb, is currently accessible in manygeneric plans. Metformin is a biguanide type insulin sharpening drug for the treatment of diabetes. The medications method of activity is by initiation of adenosine monophosphate enacted protein kinase (AMPK) a liver compound that assumes a significant job in insulin flagging, entire body vitality balance, and the digestion of glucose and fats. Actuation of AMPK applies an inhibitory effecton the creation of glucose by liver cells. Metformin is the most recommended enemy of diabetic medication on the planet and structures the essential first line treatment for treatment of type II diabetes . After an exhaustive writing overview, hardly any reports for synchronous estimation of STG and MET in pharmaceutical measurement structure and organic liquids were seen as announced including UV-spectrophotometric [3,4,5], RP-HPLC [6,7,8], UPLC [9], and laser diode warm desorption pair mass spectrometry techniques. Be that as it may, no HPTLC technique was accounted for the synchronous estimation of STG and MET in joined measurement structure yet. The current investigation portrays a straightforward, delicate and exact HPTLC strategy for the estimation of STG and MET from consolidated dose structure. Materials: Investigative unadulterated examples of STG (Merck Private Ltd., Mumbai, Maharashtra, India) and MET (BriosiaPrivate Ltd., Jejuri, Maharashtra, India) were utilized in the examination. The pharmaceutical measurements structure utilized in this examination was JANUMET(Merck Sharp and Dohme, MND Holland, Netherlands) acquired from the neighborhood market and named to contain 50 mg of STG and 500 mg of MET per tablet.